Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CareMax (CMAX – Research Report), Bausch + Lomb Corporation (BLCO – Research Report) and Arcus Biosciences (RCUS – Research Report).
CareMax (CMAX)
Truist Financial analyst Jailendra Singh maintained a Hold rating on CareMax on October 20. The company’s shares closed last Tuesday at $2.41, close to its 52-week low of $1.83.
According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of
CareMax has an analyst consensus of Hold.
See today’s best-performing stocks on TipRanks >>
Bausch + Lomb Corporation (BLCO)
In a report released today, Craig Bijou from Bank of America Securities reiterated a Buy rating on Bausch + Lomb Corporation, with a price target of $20.00. The company’s shares closed last Tuesday at $16.70.
According to TipRanks.com, Bijou is a 1-star analyst with an average return of
Currently, the analyst consensus on Bausch + Lomb Corporation is a Moderate Buy with an average price target of $19.94, representing a 21.9% upside. In a report issued on October 13, Wells Fargo also maintained a Buy rating on the stock with a $21.00 price target.
Arcus Biosciences (RCUS)
Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Arcus Biosciences today and set a price target of $23.00. The company’s shares closed last Tuesday at $15.87, close to its 52-week low of $15.52.
According to TipRanks.com, Zemansky is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcus Biosciences with a $42.10 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
